A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-67835989 in Healthy Participants
Latest Information Update: 26 Jul 2022
At a glance
- Drugs JNJ-67835989 (Primary)
- Indications Cardiovascular disorders; Dissociative disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 20 Jul 2022 Status changed from recruiting to completed.
- 21 Jun 2022 Planned End Date changed from 16 May 2022 to 2 Oct 2022.
- 01 Mar 2022 Planned primary completion date changed from 16 May 2022 to 23 Jun 2022.